Abstract Number: PB0013
Meeting: ISTH 2021 Congress
Background: ESC 2018 Guidelines of the management of arterial hypertension yet have set ACE-inhibitors and angiotensin-receptor blockers (BRA) as drugs of choice in treatment of associated pathology. We have interested in some specific pleiotropic features in the activity of them such as the influence on the state coagulation and fibrinolisys.
Aims: To learn potential activity of ramopril versus losartan on some factors of coagulation and plasma fibrinolisys during their use in patients with arterial hypertension and diabetes mellitus of type 2.
Methods: Monotherapy of ramipril (from 5 to 10 mg)(N=48) or losartan (from 50 to 100 mg) (N=41) per day were prescribed for 89 patients with arterial hypertension and diabetes mellitus type 2 on the basic use of metformin and statins for 36 weeks. The activities of protein C, antithrombin III (AT III), and factor XIII, plasma fibrinolitic activity (PFA) were measured. The estimation of efficacy was conducted by calculation of “before-after” changes, the therapeutical benefit (changes of attributable risk – CAR and odds ratio (OR).
Results: It has been established the same direction of anticoagulative activity changes under the influence of both drugs. We set the reliable increase of protein C activity (ramipril group – from 0,82±0,25u. to1,09±0,14 u. p<0,001 and losartan group – 0,86±0,22u. to 1,12±0,37 u. p<0,001), but the changes of AT III and factor XIII were unreliable. As to state of fibrinolisys, we have found the incrimination of the activity after this period of treatment. Administration of ramipril forwards more considerable raise of PFA, the absolute advantage ramipril against losartan was set at CAR=16,4%, OR = 1.92 (0,74 – 9,84).
Conclusions: Both drugs (ramipril and losartan) have a certain equal level of the influence on coagulation; however ramipril have been shown greater ability on the changes of fibrinolitic activity.
To cite this abstract in AMA style:Shorikov E, Shorikova D, Shorikov P, Khukhlina O. The Coagulation and Fibrinolisys Changes Undergoing the Ramipril and Losartan Treatment of Concomitant Arterial Hypertension and Diabetes Mellitus Type 2 [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/the-coagulation-and-fibrinolisys-changes-undergoing-the-ramipril-and-losartan-treatment-of-concomitant-arterial-hypertension-and-diabetes-mellitus-type-2/. Accessed November 29, 2023.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/the-coagulation-and-fibrinolisys-changes-undergoing-the-ramipril-and-losartan-treatment-of-concomitant-arterial-hypertension-and-diabetes-mellitus-type-2/